Summary
Global Markets Direct’s, ‘Genentech, Inc. - Product Pipeline Review - 2016’, provides an overview of the Genentech, Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Genentech, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Genentech, Inc.
- The report provides overview of Genentech, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Genentech, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Genentech, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Genentech, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Genentech, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Genentech, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Genentech, Inc. Snapshot 6
Genentech, Inc. Overview 6
Key Information 6
Key Facts 6
Genentech, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Genentech, Inc. - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Pipeline Products - Partnered Products 14
Pipeline Products - Out-Licensed Products 16
Genentech, Inc. - Pipeline Products Glance 18
Genentech, Inc. - Late Stage Pipeline Products 18
Genentech, Inc. - Clinical Stage Pipeline Products 19
Genentech, Inc. - Early Stage Pipeline Products 22
Genentech, Inc. - Drug Profiles 25
crenezumab 25
etrolizumab 27
lampalizumab 29
taselisib 31
duligotuzumab 33
ipatasertib 35
polatuzumab vedotin 37
quilizumab 39
RG-6046 40
RG-7745 41
BFKB-8488A 42
BTCT-4465A 43
DMUC-4064A 44
Drug for Inflammatory Diseases 45
DSTA-4637S 46
GDC-0134 47
GDC-0927 48
lifastuzumab vedotin 49
RG-6024 51
RG-6029 52
RG-7741 53
RG-7828 54
RG-7842 55
RG-7845 56
RG-7882 57
RG-7888 58
RG-7893 59
CS-3 60
G-007LK 61
G-244LM 62
GNE-293 63
GNE-317 64
GNE-3511 65
GNE-555 66
GNE-7915 67
GNE-892 68
MAb-30D8 69
Monoclonal Antibodies to Target CD98hc and BACE for Alzheimer's Disease 70
Monoclonal Antibody Conjugate for B-Cell Non Hodgkin's Lymphoma 71
Monoclonal Antibody Conjugates for Oncology 72
Monoclonal Antibody to Inhibit HtrA1 for Age Related Macular Degeneration 73
Monoclonal Antibody to Inhibit Tau for Alzheimer's Disease and Neurodegenerative Disorders 74
MV-1 75
pictilisib 76
Small Molecule to Inhibit BACE1 for Alzheimer’s Disease 78
Small Molecule to Inhibit MAP4K4 for Cancer 79
Small Molecule to Inhibit TYK2 for Psoriasis and IBD 80
Small Molecules to Inhibit IRAK4 for Immunology and Oncology 81
Small Molecules to Inhibit JAK2 for Cancer 82
Small Molecules to Inhibit JAK2 for Myeloproliferative Neoplasms 83
Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma 84
Small Molecules to Inhibit NAMPT for Cancer 85
Small Molecules to Inhibit PI3-Kinase Delta for Inflammatory and Leukocyte Disorders 86
Monoclonal Antibody Conjugated for Cancer 87
Small Molecule 2 for Undisclosed Indication 88
Small Molecule to Inhibit ITK for Asthma 89
Small Molecules 1 for Undisclosed Indication 90
Small Molecules for Central Nervous System Disorders 91
Small Molecules for Undisclosed Indication 92
Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation 93
Small Molecules to Inhibit EGFR for Non-Small Cell Lung Cancer 94
Small Molecules to Inhibit Jak1/2 for Hematopoietic and Immunologic diseases 95
Small Molecules to Inhibit Ubiquitin Specific Protease for Oncology 96
Genentech, Inc. - Pipeline Analysis 97
Genentech, Inc. - Pipeline Products by Target 97
Genentech, Inc. - Pipeline Products by Route of Administration 100
Genentech, Inc. - Pipeline Products by Molecule Type 101
Genentech, Inc. - Pipeline Products by Mechanism of Action 102
Genentech, Inc. - Recent Pipeline Updates 105
Genentech, Inc. - Dormant Projects 112
Genentech, Inc. - Discontinued Pipeline Products 113
Discontinued Pipeline Product Profiles 114
Genentech, Inc. - Company Statement 119
Genentech, Inc. - Locations and Subsidiaries 120
Head Office 120
Other Locations & Subsidiaries 120
Genentech, Inc. - Key Manufacturing Facilities 121
Appendix 122
Methodology 122
Coverage 122
Secondary Research 122
Primary Research 122
Expert Panel Validation 122
Contact Us 122
Disclaimer 123
List of Tables
Genentech, Inc., Key Information 11
Genentech, Inc., Key Facts 11
Genentech, Inc. - Pipeline by Indication, 2016 13
Genentech, Inc. - Pipeline by Stage of Development, 2016 17
Genentech, Inc. - Monotherapy Products in Pipeline, 2016 18
Genentech, Inc. - Partnered Products in Pipeline, 2016 19
Genentech, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 20
Genentech, Inc. - Out-Licensed Products in Pipeline, 2016 21
Genentech, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 22
Genentech, Inc. - Phase III, 2016 23
Genentech, Inc. - Phase II, 2016 24
Genentech, Inc. - Phase I, 2016 25
Genentech, Inc. - Preclinical, 2016 27
Genentech, Inc. - Discovery, 2016 29
Genentech, Inc. - Pipeline by Target, 2016 102
Genentech, Inc. - Pipeline by Route of Administration, 2016 105
Genentech, Inc. - Pipeline by Molecule Type, 2016 106
Genentech, Inc. - Pipeline Products by Mechanism of Action, 2016 107
Genentech, Inc. - Recent Pipeline Updates, 2016 110
Genentech, Inc. - Dormant Developmental Projects,2016 117
Genentech, Inc. - Discontinued Pipeline Products, 2016 118
Genentech, Inc., Other Locations 125
Genentech, Inc., Key Manufacturing Facilities 126
List of Figures
Genentech, Inc. - Pipeline by Top 10 Indication, 2016 13
Genentech, Inc. - Pipeline by Stage of Development, 2016 17
Genentech, Inc. - Monotherapy Products in Pipeline, 2016 18
Genentech, Inc. - Partnered Products in Pipeline, 2016 19
Genentech, Inc. - Out-Licensed Products in Pipeline, 2016 21
Genentech, Inc. - Pipeline by Top 10 Target, 2016 102
Genentech, Inc. - Pipeline by Route of Administration, 2016 105
Genentech, Inc. - Pipeline by Molecule Type, 2016 106
Genentech, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 107
